J&J Draws Line On Procrit Pricing; Will Not Match Amgen Aranesp 40% Discounts

Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."